Is Arbutus Biopharma Stock a Good Investment?
Arbutus Biopharma Investment Advice | ABUS |
- Examine Arbutus Biopharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Arbutus Biopharma's leadership team and their track record. Good management can help Arbutus Biopharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Arbutus Biopharma's business and its evolving consumer preferences.
- Compare Arbutus Biopharma's performance and market position to its competitors. Analyze how Arbutus Biopharma is positioned in terms of product offerings, innovation, and market share.
- Check if Arbutus Biopharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Arbutus Biopharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Arbutus Biopharma Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Arbutus Biopharma Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Arbutus Biopharma Stock
Researching Arbutus Biopharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 22.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.43. Arbutus Biopharma Corp had not issued any dividends in recent years. The entity had 1:5 split on the 4th of November 2010.
To determine if Arbutus Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arbutus Biopharma's research are outlined below:
| Arbutus Biopharma generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 18.14 M. Net Loss for the year was (72.85 M) with loss before overhead, payroll, taxes, and interest of (56.05 M). | |
| Arbutus Biopharma Corp currently holds about 150.2 M in cash with (85.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Roughly 22.0% of the company shares are held by company insiders |
Arbutus Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arbutus Biopharma Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arbutus Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Arbutus Biopharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 606.37 M.Basic technical analysis of Arbutus Stock
As of the 21st of January, Arbutus Biopharma shows the risk adjusted performance of (0.10), and Mean Deviation of 1.8. Arbutus Biopharma Corp technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Arbutus Biopharma Corp risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Arbutus Biopharma Corp is priced correctly, providing market reflects its regular price of 3.2 per share. Given that Arbutus Biopharma has information ratio of (0.14), we suggest you to validate Arbutus Biopharma Corp's prevailing market performance to make sure the company can sustain itself at a future point.Arbutus Biopharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arbutus Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arbutus Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arbutus Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arbutus Biopharma's Outstanding Corporate Bonds
Arbutus Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Arbutus Biopharma Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Arbutus bonds can be classified according to their maturity, which is the date when Arbutus Biopharma Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Arbutus Biopharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Arbutus Biopharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 1.6 | |||
| Mean Deviation | 1.8 | |||
| Coefficient Of Variation | (755.21) | |||
| Standard Deviation | 2.56 | |||
| Variance | 6.56 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.41) | |||
| Treynor Ratio | 1.59 | |||
| Maximum Drawdown | 17.48 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 3.14 | |||
| Skewness | 0.5438 | |||
| Kurtosis | 3.58 |
| Risk Adjusted Performance | (0.10) | |||
| Market Risk Adjusted Performance | 1.6 | |||
| Mean Deviation | 1.8 | |||
| Coefficient Of Variation | (755.21) | |||
| Standard Deviation | 2.56 | |||
| Variance | 6.56 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.34) | |||
| Total Risk Alpha | (0.41) | |||
| Treynor Ratio | 1.59 | |||
| Maximum Drawdown | 17.48 | |||
| Value At Risk | (4.39) | |||
| Potential Upside | 3.14 | |||
| Skewness | 0.5438 | |||
| Kurtosis | 3.58 |
Consider Arbutus Biopharma's intraday indicators
Arbutus Biopharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Arbutus Biopharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Arbutus Biopharma time-series forecasting models is one of many Arbutus Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Arbutus Biopharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Arbutus Stock media impact
Far too much social signal, news, headlines, and media speculation about Arbutus Biopharma that are available to investors today. That information is available publicly through Arbutus media outlets and privately through word of mouth or via Arbutus internal channels. However, regardless of the origin, that massive amount of Arbutus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arbutus Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arbutus Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arbutus Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arbutus Biopharma alpha.
Arbutus Biopharma Corporate Management
| BA Esq | General Officer | Profile | |
| Gaston Picchio | Chief Officer | Profile | |
| Lisa Caperelli | Vice Relations | Profile | |
| David CPA | CFO Officer | Profile | |
| William Collier | CEO Pres | Profile | |
| Elizabeth Howard | Gen VP | Profile |
Already Invested in Arbutus Biopharma Corp?
The danger of trading Arbutus Biopharma Corp is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arbutus Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arbutus Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arbutus Biopharma Corp is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.